Abstract
Unlike many other areas of therapeutics, specific regulatory trial programmes are required to be undertaken in newly diagnosed epilepsy to support the licensing of novel antiepileptic drugs for use in drug-naïve patients. To complicate matters further, American and European regulators have taken markedly different approaches to this issue, with the FDA requiring withdrawal to monotherapy data comparing more than one dose of newer agents with historical controls, whereas the EMA recommends undertaking randomised head-to-head studies versus an established comparator. The former studies are designed to show superiority compared to previously published data, whereas the latter will accept a non-inferiority (equivalence) outcome. This paper discusses the positive and negative aspects of both designs and explores novel alternative options. Particular focus has been placed on placebo-controlled studies following a single seizure with supportive electroencephalographic and/or brain imaging evidence, in the hope of identifying a realistic design that will satisfy licensing authorities on both sides of the Atlantic Ocean.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baulac M, Brodie MJ, Patten A, Segieth J, Georgi L. Comparison of the efficacy and tolerability of zonisamide and controlled-release carbamazepine in newly diagnosed epilepsy. Lancet Neurol 2012 (submitted).
Brodie MJ, Wroe SJ, Dean APD, Holdich TAH, Whitehead J, Stevens JN. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 2002; 3: 140–146.
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408.
Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78: 1548–1554.
Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011; 52: 619–626.
Chadwick D, Privitera M. Placebo-controlled studies in neurology. Where do they stop? Neurology 1999; 52: 682–685.
Committee for Medicinal Products for Human Use. Recommendations of revision of the note for guidance on clinical investigation of medicinal products in treatment of epileptic disorders. (CPMP/EWP/566/98-rev1). London: European Medicines Agency, 2000. http://www.emea.europa.EU/pdfs/human/ewp/05669en.pdf [accessed November 1, 2011].
Fisher RS, Van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470–472.
Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Peripheral and Central Nervous System Drugs Advisory Committee meeting. March 10, 2011 [Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralCentralNervousSystemDrugsAdvisoryCommittee/UCM250489.pdf (accessed November 1, 2011].
French JA, Wang S, Warnock B, Tempkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010; 51: 1936–1943.
French JA, Temkin NR, Sneker BF, Hammer AE, Caldwell MS, Messenheimer JA. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics 2012; 9: 176–184.
Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug therapy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–1120.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–319.
Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255–1260.
Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60: S2–S12.
Kwan P, Brodie MJ, Kalviainen R, Yurkewicz L, Weaver J, Knapp L. Pregabalin versus lamotrigine for newly diagnosed partial seizures: a double-blind, randomised, parallel group trial. Lancet Neurol 2011; 10: 881–890.
Leone MA, Solari A, Beghi E; FIRST Group. Treatment of the first tonic-clonic seizure does not affect long-term remission in epilepsy. Neurology 2006; 67: 2227–2229.
Leschziner G, Jorgensen AL, Andrew T, et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol 2006; 5: 668–676.
Macdonald BK, Johnson AL, Goodridge GM. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48: 833–841.
Marson A, Jacoby A, Kim L, Gamble C, Chadwick D. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365: 2007–2013.
Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after foetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597–1605.
Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur Neurol 2006; 13: 277–282.
Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonicclonic seizure does not improve the prognosis of epilepsy. Neurology 1997; 49: 991–998.
Neligan A, Bell GS, Sander JW, Shorvon SD. How refractory is refractory epilepsy? Patterns of relapse and remission in people with refractory epilepsy. Epilepsy Res 2011; 96: 225–230.
Perucca E. When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia 2010; 51: 1933–1935.
Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247–262.
Porter RJ, Baulac M, Nohria V. Clinical development of drugs for epilepsy; a review of approaches in the United States and Europe. Epilepsy Res 2010; 89: 163–175.
Schiller Y. Seizure relapse and development of drugresistance following long-term remission. Arch Neurol 2009; 66: 1233–1239.
Sooriyarachchi MR, Whitehead J. A method for sequential analysis of survival data with non-proportional hazards. Biometrics 1998; 54: 1072–1084.
Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609–617.
Whitehead J. Monotherapy trials: sequential design. Epilepsy Res 2001; 45: 81–87.
Whitehead J, Todd S. The double triangular test in practice. Pharmaceutical Statistics 2004; 3: 39–49.
Author information
Authors and Affiliations
Corresponding author
Additional information
Updated following presentation and discussion at the 2011 Progress in Epileptic Disorders Workshop on “Antiepileptic Drug Trials: will the future challenge the past” held at the Chaeauform’ La Maison des Contes, Dareizé, 69490, France. The workshop was partly supported by an educational grant from UCB. The program was under the exclusive responsibility of a Scientific Committee composed by Prs. Philippe Ryvlin (France), Emilio Perucca (Italy), Jackie French (USA), Steve White (USA), Graeme Sills (UK) and Alexis Arzimanoglou (France).
About this article
Cite this article
Brodie, M.J. Novel trial designs for monotherapy. Epileptic Disord. 14, 132–137 (2012). https://doi.org/10.1684/epd.2012.0513
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0513